Sarah Schellhorn (Mougalian)
@SESchellhorn
Followers
207
Following
69
Media
4
Statuses
44
Breast cancer doc, educator, researcher. Passionate about quality of cancer care. All tweets are my own.
New Haven, CT
Joined April 2019
Such a privilege to work in a fantastic cancer center with amazing colleagues and patients.
Sarah Schellhorn Mougalian, MD @SMougalian, focuses her care on patients with #breastcancer, working closely with a multidisciplinary team to address every patient's goals & treatment options. #bcsm Read more from Dr. Mougalian https://t.co/1nNvqzQCRC
@SmilowCancer @YaleMed @YNHH
0
0
6
Amazing work on outcomes and race in early-stage TNBC receiving durvalumab! #ASCO22 #breastcancer #equity @JuliaFoldiMD @YaleHemOnc @YaleCancer @SmilowCancer
0
3
22
.@NorinAnsariMD will present new data highlighting differences in mutations between younger and older patients with #breastcancer in a poster session this morning #ASCO22 in Hall A. #bcsm @maryam_lustberg @MariyaRozenblit @SmilowCancer @YaleMed
1
7
20
Outstanding piece by my amazing colleague, Dr. Tara Sanft, on the emotions we face as physicians caring for patients at the end of life. @tarasanftmd @maryam_lustberg
https://t.co/xsusXlFiYi
academic.oup.com
Is it okay to cry with your patients? This narrative tells a story to help answer this complicated question.
2
1
12
This guy: the epitome of mentorship. I’m honored to work with him.
Huge congratulations to our incredible director, @cpgYALE, on receiving the Yale Cancer Center Award for Mentorship Excellence! 🎉 Such a well-deserved recognition for a generous and talented mentor and collaborator! @YaleCancer @YaleMed @NCSP_Yale
0
2
12
At this year’s #SABCS, Dr. Mariya Rozenblit presented new research observing longer survival times for #breastcancer patients using everolimus exemestane as a third line treatment following prior CDK4/6 inhibitor therapy. @SmilowCancer @YaleMed @YNHH @SMougalian @SABCSSanAntonio
0
3
3
Fantastic organization! Please vote every day!
0
0
0
Fantastic reminder! Using this today in a letter for an accomplished, already successful mentee.
0
0
1
Thanks @SUMOncol for the invitation to present in beautiful Park City, UT! Great to spend time chatting with @marklewismd @ClarkeLow @YaleCancer
.@SMougalian @YaleCancer speaks to @SUMOncology on the explosion of new FDA-approved therapies in breast cancer in the last several years cc: @MVanMeterMD #bcsm Sequencing of treatment remains a major area of investigation
0
0
5
Take 2 Aspirin? How about take 2 seconds to look at data showing the impact of decades of reliance on biomedical model: persistent inequity in #cancer (& other) outcomes. https://t.co/e1WtyiYx7l Only redeeming feature of this @WSJ piece: author is FORMER dean of curriculum.
2
3
33
Great to see the full range of @YaleCOPPER work from screening to end of care at #ASCOQLTY19. Congrats to @NataliaKunst, Amy Davidoff
0
2
10
New findings in #breastcancer research journal led by .@SMougalian and Dr. Bridget Killela finds women receiving neoadjuvant #endocrinetherapy had simliar rates of breast conservation surgery compared to neoadjuvant #chemotherapy. @YaleMed @YNHH
https://t.co/8uBXwAzvNP
0
3
12
Thank you @YaleCancer @DrRoyHerbstYale for the opportunity. Great to meet and reconnect with local and not-so-local oncologists!
.@SMougalian leads a discussion of #breastcancer cases and treatment pathways at #YaleASCO19 with highlights of practice changing data from #ASCO19 @ASCO @YaleMed @YNHH
0
0
1
Thrilled to be acknowledged by our heme/onc fellows! It is indeed an honor and a privilege, and congratulations to all 2019 graduates!
Congratulations to @SMougalian of Yale Medical Oncology @YaleCancer winner of the 2019 teaching award as chosen by our graduating fellows @YNHH @YaleMedicine @YaleMed. Pictured here with fellowship director Dr. Jill Lacy.
2
0
21
From @nytopinion: Corporate medicine has milked just about all the “efficiency” it can from the health care system. But one resource seems endless — and free: the professionalism of doctors and nurses, who are overworked and burning out.
31
540
901
Eloquent review of low dose tam and PRS in breast cancer prevention by Dr Erin Hoffstatter @YaleCancer. We need better ABC’s - Agents, Biomarkers, Cohort Selection. 👈 Really an outstanding presentation and exciting to see some movement in breast cancer prevention! #ASC019
0
2
4
Colleagues: could we consider referring to “patient deaths” instead of “grade 5 events?” Let’s keep it patient-centered. #ASCO19
0
1
10
Nonadherence to aromatase inhibitors is common. A simple text messaging intervention study was negative. —@DrDawnHershman #ASCO19 #bcsm #SWOGOnc
3
16
32
Getting ready to discuss LBA1 @ASCO plenary! I'm live tweeting thx to @DukeGUCancer. Follow to see why this study is worthy of the plenary stage: 1) It is practice changing 2) It’s a proof-of-concept that health policy can improve cancer quality and reduce disparities #ASCO19
1
10
28